Cvrx COO Brent Binkowski sells $3,338 in company stock By Investing.com

Brent Binkowski, Chief Operating Officer of CVRx, Inc. (), sold 1,309 shares of the company’s common stock on August 12, 2026. The transactions totaled $3,338, with shares sold at prices ranging from $2.55 to $2.564 per share. The stock currently trades at $2.94, rebounding 23% over the past week but still down 59% year-to-date. According to InvestingPro analysis, CVRX appears undervalued at current levels, with the stock among names on the platform’s Most Undervalued list.

The sale was a sell-to-cover transaction, mandated by the issuer’s award agreement to satisfy tax withholding obligations. Following this transaction, Mr. Binkowski directly holds 30,291 shares of CVRx common stock. For deeper insights into CVRX’s financial health and valuation, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.

In other recent news, CVRx reported its second-quarter revenue at $15.7 million, marking a 16% increase from the previous year and slightly surpassing Wall Street’s estimate of $15.55 million. Despite this growth, the company has lowered its full-year revenue outlook, citing challenges related to sales force execution and reimbursement issues with its largest payer. Piper Sandler responded to these developments by downgrading CVRx’s stock rating from Overweight to Neutral and reducing the price target from $12.00 to $4.00. The downgrade was influenced by the company’s second-quarter earnings call, where management highlighted ongoing sales force issues and inconsistent reimbursement. These factors have contributed to a cautious outlook for the company’s financial performance. The recent revenue growth was driven by stronger sales of the U.S. Barostim product. However, the company’s revised guidance and management’s comments on turnover and territory ramping have raised concerns among investors. As CVRx navigates these challenges, the focus remains on addressing sales force and reimbursement issues to stabilize its financial outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.